Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Tipo de estudio
Intervalo de año de publicación
1.
Cell Death Differ ; 27(8): 2534, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32152554

RESUMEN

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

2.
Cell Death Differ ; 27(5): 1588-1603, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-31685979

RESUMEN

Heterozygous mutations of the lysosomal enzyme glucocerebrosidase (GBA1) represent the major genetic risk for Parkinson's disease (PD), while homozygous GBA1 mutations cause Gaucher disease, a lysosomal storage disorder, which may involve severe neurodegeneration. We have previously demonstrated impaired autophagy and proteasomal degradation pathways and mitochondrial dysfunction in neurons from GBA1 knockout (gba1-/-) mice. We now show that stimulation with physiological glutamate concentrations causes pathological [Ca2+]c responses and delayed calcium deregulation, collapse of mitochondrial membrane potential and an irreversible fall in the ATP/ADP ratio. Mitochondrial Ca2+ uptake was reduced in gba1-/- cells as was expression of the mitochondrial calcium uniporter. The rate of free radical generation was increased in gba1-/- neurons. Behavior of gba1+/- neurons was similar to gba1-/- in terms of all variables, consistent with a contribution of these mechanisms to the pathogenesis of PD. These data signpost reduced bioenergetic capacity and [Ca2+]c dysregulation as mechanisms driving neurodegeneration.


Asunto(s)
Calcio/metabolismo , Metabolismo Energético , Glucosilceramidasa/deficiencia , Neuronas/patología , Adenosina Difosfato/metabolismo , Adenosina Trifosfato/metabolismo , Animales , Encéfalo/patología , Radicales Libres/metabolismo , Glucosilceramidasa/metabolismo , Ácido Glutámico/toxicidad , Homeostasis/efectos de los fármacos , Metabolismo de los Lípidos/efectos de los fármacos , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Ratones Noqueados , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Neuronas/efectos de los fármacos , Receptores de Glutamato/metabolismo
3.
Hum Mol Genet ; 28(12): 2001-2013, 2019 06 15.
Artículo en Inglés | MEDLINE | ID: mdl-30753527

RESUMEN

Parkinson's disease (PD) is the second most common neurodegenerative disorder and a central role for α-synuclein (αSyn; SNCA) in disease aetiology has been proposed based on genetics and neuropathology. To better understand the pathological mechanisms of αSyn, we generated induced pluripotent stem cells (iPSCs) from healthy individuals and PD patients carrying the A53T SNCA mutation or a triplication of the SNCA locus and differentiated them into dopaminergic neurons (DAns). iPSC-derived DAn from PD patients carrying either mutation showed increased intracellular αSyn accumulation, and DAns from patients carrying the SNCA triplication displayed oligomeric αSyn pathology and elevated αSyn extracellular release. Transcriptomic analysis of purified DAns revealed perturbations in expression of genes linked to mitochondrial function, consistent with observed reduction in mitochondrial respiration, impairment in mitochondrial membrane potential, aberrant mitochondrial morphology and decreased levels of phosphorylated DRP1Ser616. Parkinson's iPSC-derived DAns showed increased endoplasmic reticulum stress and impairments in cholesterol and lipid homeostasis. Together, these data show a correlation between αSyn cellular pathology and deficits in metabolic and cellular bioenergetics in the pathology of PD.


Asunto(s)
Neuronas Dopaminérgicas/metabolismo , Células Madre Pluripotentes Inducidas/metabolismo , Mitocondrias/metabolismo , Enfermedad de Parkinson/genética , alfa-Sinucleína/genética , Diferenciación Celular , Dinaminas/metabolismo , Estrés del Retículo Endoplásmico/genética , Metabolismo Energético/genética , Humanos , Metabolismo de los Lípidos/genética , Potencial de la Membrana Mitocondrial , Mitocondrias/ultraestructura , Mutación , Enfermedad de Parkinson/metabolismo , RNA-Seq , Sinucleinopatías/metabolismo , alfa-Sinucleína/metabolismo
4.
Sci Rep ; 7(1): 9003, 2017 08 21.
Artículo en Inglés | MEDLINE | ID: mdl-28827786

RESUMEN

To examine the pathogenic role of α-synuclein (αS) in Parkinson's Disease, we have generated induced Pluripotent Stem Cell lines from early onset Parkinson's Disease patients with SNCA A53T and SNCA Triplication mutations, and in this study have differentiated them to PSC-macrophages (pMac), which recapitulate many features of their brain-resident cousins, microglia. We show that SNCA Triplication pMac, but not A53T pMac, have significantly increased intracellular αS versus controls and release significantly more αS to the medium. SNCA Triplication pMac, but not A53T pMac, show significantly reduced phagocytosis capability and this can be phenocopied by adding monomeric αS to the cell culture medium of control pMac. Fibrillar αS is taken up by pMac by actin-rearrangement-dependent pathways, and monomeric αS by actin-independent pathways. Finally, pMac degrade αS and this can be arrested by blocking lysosomal and proteasomal pathways. Together, these results show that macrophages are capable of clearing αS, but that high levels of exogenous or endogenous αS compromise this ability, likely a vicious cycle scenario faced by microglia in Parkinson's disease.


Asunto(s)
Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Fagocitosis/efectos de los fármacos , alfa-Sinucleína/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Diferenciación Celular , Femenino , Dosificación de Gen , Humanos , Masculino , Persona de Mediana Edad , Mutación Missense , Enfermedad de Parkinson/patología , Células Madre Pluripotentes , alfa-Sinucleína/genética
5.
Stem Cell Reports ; 9(2): 587-599, 2017 08 08.
Artículo en Inglés | MEDLINE | ID: mdl-28689993

RESUMEN

The H1 haplotype of the microtubule-associated protein tau (MAPT) locus is genetically associated with neurodegenerative diseases, including Parkinson's disease (PD), and affects gene expression and splicing. However, the functional impact on neurons of such expression differences has yet to be fully elucidated. Here, we employ extended maturation phases during differentiation of induced pluripotent stem cells (iPSCs) into mature dopaminergic neuronal cultures to obtain cultures expressing all six adult tau protein isoforms. After 6 months of maturation, levels of exon 3+ and exon 10+ transcripts approach those of adult brain. Mature dopaminergic neuronal cultures display haplotype differences in expression, with H1 expressing 22% higher levels of MAPT transcripts than H2 and H2 expressing 2-fold greater exon 3+ transcripts than H1. Furthermore, knocking down adult tau protein variants alters axonal transport velocities in mature iPSC-derived dopaminergic neuronal cultures. This work links haplotype-specific MAPT expression with a biologically functional outcome relevant for PD.


Asunto(s)
Diferenciación Celular/genética , Neuronas Dopaminérgicas/citología , Neuronas Dopaminérgicas/metabolismo , Variación Genética , Células Madre Pluripotentes Inducidas/citología , Proteínas tau/genética , Alelos , Transporte Axonal , Células Cultivadas , Exones , Expresión Génica , Técnicas de Silenciamiento del Gen , Haplotipos , Humanos , Mitocondrias/metabolismo , Enfermedad de Parkinson/genética , Enfermedad de Parkinson/metabolismo , Isoformas de Proteínas , Proteínas tau/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA